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fined to patients previously not using oral beta-blockers.
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869-3 Aqueous Oxygen Therapy for ST Segment Elevation 
Myocardial Infarction: AMIHOT Trial Safety Report and 
Enrollment Completion
Jack L. Martin, Francis Day, Simon Dixon, Douwe Atsma, Pranobe Oemrawsingh, 
Catherine Pensyl, Barbara Lindsay, Antonio Bartorelli, William O'Neill, Main Line Health 
System, Bryn Mawr, PA, William Beaumont Hospital, Royal Oak, MI
Background: Although rapid coronary reperfusion in ST segment elevation myocardial
infarction (STEMI) improves left ventricular function and mortality, epicardial vessel
patency does not fully ensure nutrient flow at the tissue level. Animal and Phase I human
testing of the TherOx® Aqueous Oxygen (AO) System (TherOx Inc., Irvine, California)
suggests that percutaneous coronary infusion of autologous blood mixed with hyperox-
emic saline may help overcome the downstream barrier to oxygen delivery in ischemic
zones and improve myocardial salvage following percutaneous intervention for STEMI.
Methods: A Phase II randomized international trial is designed to evaluate the efficacy of
regional AO therapy in STEMI.A sub-selective catheter positioned in the infarct artery
delivers AO for 90 minutes at 75 ml/minute. Contrast echocardiography performed follow-
ing intervention and before randomization is repeated at 24 hours, and days 30 and 90.
Resting SPECT myocardial perfusion scans are obtained day 14. Primary endpoints
include regional wall motion scores, SPECT perfusion defects, and ST segment resolu-
tion.
Results: Two hundred patients have been randomized after 20 run-in cases. None of the
100 patients assigned to treatment experienced hemodynamic or electrophysiologic
instability during infusion. Repeat angiography when performed following AO therapy
documented perfusion catheter stability and maintenance of TIMI 3 flow. Planned interim
analysis performed after randomization of the first 200 patients demonstrated no safety
concerns and there were no unanticipated major cardiac events. Enrollment of the 270
patient cohort is to be completed by January, 2003.
Conclusion: Preliminary results suggest that regional hyperoxemic therapy appears to
be safe and can be readily applied in institutions performing primary angioplasty for
STEMI. Conclusions regarding the promise of this new therapeutic modality to improve
recovery of left ventricular function requires longer-term follow up.
9:15 a.m.
869-4 Sex Disparities in the Treatment of Non–ST-Segment 
Elevation Acute Coronary Syndromes
Andra L. Blomkalns, L. Kristin Newby, Anita Chen, Eric D. Peterson, Kelly Trynosky, 
Deborah Diercks, William E. Boden, Matthew T. Roe, E. Magnus Ohman, W. Brian Gibler, 
Judith S. Hochman, University of Cincinnati, Cincinnati, OH, Duke Clinical Research 
Institute, Durham, NC
Background: No large-scale examination of sex disparities in the management of acute
coronary syndromes (ACS) has been done since publication of the revised ACC/AHA
Guidelines for the Diagnosis and Treatment of non–ST-elevation acute coronary syn-
dromes (NSTE ACS).
Methods: We conducted a retrospective data analysis from the CRUSADE Initiative,
which enrolls US pts with NSTE ACS (ST-segment depression or transient elevation or
positive cardiac markers). We examined sex differences in the use of acute and dis-
charge medications, in-hospital procedures, discharge interventions, and in-hospital out-
comes.
Results: Of the 35,835 pts (41% women) in the study, women were older and had more
diabetes and hypertension but less prior MI or revascularization (Table). Women less
often received acute aspirin, heparin, GP IIb-IIIa or ACE inhibitors. Discharge treatments
were similarly disparate for use of aspirin, beta blockers, ACE inhibitors, and statins.
Women were at higher risk for death (5.6% vs 4.3%, p<0.0001), post-admission MI (4.0%
vs 3.5%, p=0.03), CHF (12.1% vs 8.8%, p<0.0001), stroke (1.1% vs 0.8%, p<0.003), and
RBC transfusion (17.2% vs 13.2%, p<0.01).
Conclusion: Despite having higher-risk characteristics at presentation and greater in-
hospital risk, women with NSTE ACS are consistently treated less aggressively than
men. Lower use of evidence-based therapies was observed in women even after adjust-
ing for important differences between groups.
9:30 a.m.
869-5 Primary Angioplasty Is More Cost-Effective Than 
Prehospital Thrombolysis for Patients Within 90 
Minutes From a Percutaneous Coronary Intervention 
Center: One-Year Follow-Up of a CAPTIM Substudy
Gerald Vanzetto, Eric Bonnefoy, Helene Bouvaist, Stephanie Marliere, Jean Cassagnes, 
Paul Touboul, Jacques Machecourt, The CAPTIM Study Investigators, University 
Hospital, Grenoble, France
Background: In the CAPTIM study, primary coronary angioplasty (PCA) was as efficient
as pre-hospital thrombolysis (PHT) in patients (pts) with acute myocardial infarction (MI)
within 90 minutes from a coronary intervention (PCI) center. We compared the in-hospital
and 1 year cost-effectiveness of PCA and PHT in a predefined subset of pts from the
CAPTIM study.
Methods: 299 consecutive pts were used for analysis (PCA n=149, PHT n=150, men
80%, mean age=59±12 yrs, anterior wall MI 46%). For each pts, real costs were obtained
for pre-hospital care, key hospital resources, medications, biological and X-rays examina-
tions, catheterization devices, and staff. One year cumulative costs included costs of ini-
tial hospital, plus medications, rehabilitation, examinations, angiographies,
revascularizations and re-hospitalizations occuring after the acute phase.
Results: The 2 groups were similar for baseline data and characteristics of MI. Initial
hospitalization was shorter after PCA than after PHT (9.5 vs. 10.5 days, p=0.009), due to
more frequent emergent or planned angioplasty in the PHT group (42% vs 10%
p<0.001). Median in-hospital real cost were 6097 and 6857 € in the PCA and PHT
respectively (p=0.008). Results at 1 year follow-up (100% completed) are listed bellow.
Conclusion: When compared to PHT, PCA is a dominant strategy for treatment of MI in
pts within 90 minutes of a PCI center, driven by a shorter in-hospital stay and a significant
reduction of non planned revascularizations.
9:45 a.m.
869-6 Beneficial Effects of Combined Thrombolytic Therapy 
and Percutaneous Coronary Angioplasty in Transfer 
Patients With ST Segment Elevation Myocardial 
Infarction: A Report From the American College of 
Cardiology-National Cardiovascular Data Registry
Daniel P. O'Neill, Peter Y. M. Hui, Rupsa R. Yee, Richard Gray, Richard E. Shaw, 
American College of Cardiology - National Cardiovascular Data Registry, Bethesda, MD
Background: Prior studies have compared the efficacy of inter-hospital transport for pri-
mary percutaneous coronary intervention (PCI) versus immediate thrombolysis at a non-
PCI institution in the setting of acute myocardial infarction. The role of thrombolytics prior
to transfer has not been clearly defined and remains controversial. The objective of this
study was to compare outcomes in patients with ST segment elevation MI (STEMI) trans-
ferred with or without thrombolytic therapy for PCI to a referral institution.
Methods: Between January 1, 2001 and March 31, 2003, data on 278,105 PCI proce-
dures were submitted from 304 institutions to the American College of Cardiology
National Cardiovascular Data Registry (ACC-NCDR). Of these, 15,832 involved STEMI
patients transferred for PCI. Thrombolytic therapy was initiated in 8,326 (52.6%) and
7,506 (47.4%) were transferred without thrombolytics. Multiple post-PCI outcomes such
as mortality, emergent surgery and renal failure were analyzed following PCI at the pri-
mary institution. 
Comparison of Treatments
 Women  Men Adjusted OR (95% CI)
Acute Interventions, n (%)
Aspirin 11,960 (89.6) 18,362 (91.6) 0.87 (0.81- 0.93)
Heparin (any) 10,929 (80.0) 16,993 (84.0)  0.92 (0.88-0.98)
Beta blocker 10,007 (75.8) 15,196 (77.7)  0.99 (0.94-1.04)
ACE inhibitor 5,551 (42.4) 8,176 (42.2)  0.95 (0.91-1.00)
GP IIb-IIIa inhibitor 3,574 (28.7) 7,261 (38.6)  0.86 (0.82-0.92)
Procedure Use, n (%)
Diagnostic cath 8,701 (60.1) 15,106 (71.1)  0.86 (0.81-0.91)
PCI 4,516 (31.4) 8,555 (40.4)  0.91 (0.86-0.96)
CABG 1,284 (9.0) 2,941 (14.0)  0.59 (0.54-0.64)
One year cumulative costs (Euros) and events (n,%)
PCA PHT P value
Cardiac death 12 (8.4) 12 (8.2) NS
Recurrence of non fatal MI 7 (4.9) 12 (8.2) NS
Stroke 2 (1.4) 3 (2.0) NS
Death + MI + Stroke (MACEs) 20 (14.0) 24 (16.4) NS
MACEs + unscheduled revascularization 43 (31.8) 85 (61.1) 0.001
Median 1 year cumulative cost /patient 7427 8478 0.04
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Results: Compared to patients transferred without thrombolytic therapy (NOTHRM),
patients transferred on thrombolytic therapy (THRM) had a lower rate of mortality post
PCI (3.2% vs. 5.8%; p <0.0001), less post-PCI renal failure (1.4% vs. 2.2%; p<0.0001)
and were less like to have emergency surgery post PCI (0.4% vs. 0.7%). Based on a val-
idated mortality risk model, the observed mortality of the THRM patients was identical to
the expected mortality from the model (ratio O/E=1.0), whereas the NOTHRM patients
had a much worse than expected observed mortality (ratio O/E=1.4). Total occlusion of
the infarct-related artery was found less frequently on angiography in THRM compared to
NOTHRM (24.7% vs. 49.2%; p<0.0001).
Conclusion: In the setting of STEMI, transferred patients who received thrombolytic
therapy had better outcomes following PCI than those who did not. Transferred patients
who did not receive thrombolytics had higher PCI mortality, perhaps due to an increased
rate of occluded infarct-related artery prior to PCI. Further studies are needed to evaluate
the benefit of combined thrombolytic therapy and transfer PCI in the setting of STEMI.
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883-2 The Association of Race With Angiographic and Clinical 
Outcomes Following Fibrinolytic Administration
Pedro Martinezclark, Dimitri Karmpaliotis, Sabrina A. Murphy, Stephen D. Wiviott, Brian 
Bigelow, Ioanna Kosmidou, Allen Chang, Christopher P. Cannon, Robert P. Giugliano, C. 
Michael Gibson, Beth Israel Deaconess Medical Center, Boston, MA, TIMI Data 
Coordinating Center, Boston, MA
Background: The association of race with angiographic and clinical outcomes following
fibrinolytic administration is unclear. Objectives and Methods: To assess whether there
are racial differences in response to fibrinolytic administration in the treatment of acute
myocardial infarction. A total of 17,663 patients (16,366 Caucasians and 1,297 non-Cau-
casians) from the TIMI 4, 10A, 10B, and 14 and InTIME-2 trials were analyzed. TIMI flow
grade (TFG), corrected TIMI frame count (CTFC), TIMI myocardial perfusion grade
(TMPG), and electrocardiographic (ECG) data were available in 2,596 patients. Results:
Baseline comorbidities were increased among non-Caucasians including the incidence
of hypertension (p<0.001), diabetes (p<0.001), active cigarette smoking (p=0.006) and a
longer time to treatment (p<0.001). Angiographic outcomes did not differ by race when
stratified by use of low dose fibrinolysis combined with full dose platelet glycoprotein IIb/
IIIa receptor inhibition. Mortality was significantly lower among African-American patients
vs others (2.64% vs. 6.45%, p=0.012), even when adjusting for age, gender, systolic
blood pressure, pulse, history of hypertension, diabetes, or CHF, prior MI, Killip class on
admission, smoking, anterior MI location, and time to treatment (O.R. 0.34, 95% CI 0.12-
0.92, p=0.034). Recurrent MI trended lower in African-American patients (3.0% vs. 5.0%,
p=0.15). The composite of death or recurrent MI was significantly lower in African-Ameri-
can patients (5.3% vs 10.6%, p=0.005) as was CHF (3.8% vs 10.25%, p=0.001). How-
ever, when region of the patients’ enrollment (North American, Latin American, Eastern
Europe, Western Europe) was added to the model, the odds ratio for neither death nor
the composite of death/MI remained significant. There was no difference in the incidence
of ICH or major bleeding complications. Conclusion: After adjustment for baseline char-
acteristics and geographic region of enrollment, race was not independently associated
with clinical outcomes.
11:00 a.m.
883-3 Effects of Fish Oil Supplements on Human Myocardial 
Omega-3 Fatty Acid Levels and Correlations With 
Erythrocytes
Scott A. Sands, Hakim Ali, Phillip Mann, Anthony Magalski, Tracy L. Stevens, William S. 
Harris, Mid America Heart Institute, Kansas City, MO, University of Missouri-Kansas City, 
Kansas City, MO
Background: Omega-3 fatty acids (FA) have beneficial effects on the cardiovascular sys-
tem and are now recommended by the American Heart Association (AHA). Their primary
effect appears to be a reduction in risk for sudden cardiac death. Cell culture and animal
experiments suggest that once incorporated into the myocardium, omega-3 FA [espe-
cially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] increase the resis-
tance of the heart to ventricular fibrillation, apparently by altering the dynamics of sodium
and calcium channel function. However, whether the omega-3 FA tissue levels achieved
in these in vitro experiments was physiologically meaningful or not is unknown. The pur-
poses of this study were to determine the effects of supplementation with AHA-recom-
mended amounts of omega-3 FA on human myocardial FA composition, and to compare
the response of the heart to that of a more readily available tissue, the red blood cell
(RBC).
Methods: Twenty-one, medically-stable heart transplant recipients at least 3 months post
transplant were recruited. Heart biopsies and blood samples were obtained before and
after 6 months supplementation with 1 g/day of EPA+DHA (600 mg EPA and 400 mg
DHA; Ocean Nutrition Canada, Nova Scotia, Canada). The extent of omega-3 FA incor-
poration into these tissues was examined using gas chromatography.
Results: Supplementation raised the EPA+DHA content of the heart by 73% and of the
RBC by 93% (p=0.001 for both). The increases differed for these two FA, however. In the
heart, EPA increased by 216% (from 0.2% to 0.6% of total FA) and in the RBC by 257%
(from 0.4% to 1.5%). For DHA, the increases were 54% in the heart (from 1.5% to 2.3%)
and 78% in the RBC (from 4.2% to 7.8%).
Conclusion: These findings indicate that AHA-recommended intakes of omega-3 FA sig-
nificantly increase human myocardial EPA+DHA content, and that these changes may be
tracked by measurement of RBC EPA+DHA. The myocardial omega-3 FA levels
observed here may be used as physiologically-relevant benchmarks for future in vivo and
in vitro experiments to explore the cellular mechanisms responsible for the cardioprotec-
tive effects of omega-3 FA.
11:15 a.m.
883-4 Myocardial Ischemia-Reperfusion Injury Is Dependent 
on Lectin Complement Activation
Mary C. Walsh, Todd Bourcier, Kazue Takahashi, Lei Shi, Alan Ezekowitz, Gregory L. 
Stahl, Brigham and Women's Hospital, Boston, MA, Massachusetts General Hospital, 
Boston, MA
Background: Complement C5 activation mediates myocardial injury following myocar-
dial ischemia-reperfusion (MI/R). Complement activation is thought to result from natural
antibodies binding to neo-epitopes on injured cells, resulting in classical pathway activa-
tion and PMN infiltration. Therefore, we evaluated the contribution of the lectin and classi-
cal pathway in MI/R injury using MBL-null (MBL-A/CKO), C1q-deficient (C1qKO), C2- and
factor B-deficient (C2/Bf) or wild-type (WT) mice.
Methods: The LAD of each experimental animal was reversibly ligated for 30 min, fol-
lowed by 3 h of reperfusion. After 3 h the LAD was re-ligated to establish healthy tissue
and area at risk myocardium. Hearts were then stained for infarction and C3 or C1q dep-
osition. Myocardial infarction (MI) is expressed as a percentage of the area at risk (inf-
arct/area at risk x 100).
Results: MI/R induced significantly larger MI in WT, compared to C2/Bf mice (33±2 vs.
12±2%, respectively; p<0.05). Addition of human C2 to C2/Bf significantly increased MI
to 43±9%, comparable to WT mice and demonstrating that MI/R injury is mediated via
classical and/or lectin pathway activation. WT or C1qKO mice undergoing MI/R demon-
strated myocardial C3 deposition, thus demonstrating complement activation. WT mice
following MI/R demonstrated C1q deposition in the myocardium, whereas C1qKO mice
did not. C1qKO mice demonstrated a MI of 47±7%, and anti-C5 mAb treatment signifi-
cantly (p<0.05) reduced the infarction to 12±4%. Additionally, MBL null mice demonstrate
significantly decreased MI (4+2%; p<0.05) in comparison to WT mice following experi-
mental MI/R. However, addition of recombinant MBL to MBL null mice significantly
increased MI to 25±8%.
Conclusions: Collectively, these data demonstrate that complement activation contrib-
utes to MI/R injury. The complement system is not activated during MI/R by a C1q depen-
dent mechanism, yet C1q is deposited. Importantly, MBL null mice demonstrate little to
no infarct following experimental MI/R, yet injury is re-established upon addition of MBL.
Ultimately, these findings demonstrate the therapeutic potential of lectin complement
pathway blockade in MI/R and ischemic heart disease.
11:30 a.m.
883-5 Cardioprotective Effects of Rosiglitazone Against 
Ischemia-Reperfusion Injury Are Associated With 
Modulation of Angiotensin Receptor Expression and 
Signaling
Behzad Molavi, Jawahar L. Mehta, University of Arkansas for Medical Sciences, Little 
Rock, AR, Central Arkansas Veterans Healthcare System, Little Rock, AR
Background
Myocardial ischemia-reperfusion injury is associated with the upregulation of renin-
angiotensin system, which accentuates ischemia-reperfusion injury. The PPAR-γ ligand
rosiglitazone has been shown to exert anti-inflammatory and cardioprotective effects dur-
ing ischemia-reperfusion. We hypothesized that the cardioprotection by rosiglitazone is
associated with alterations in angiotensin II (Ang II) receptor expression.
Methods
Male S-D rats were fed either a rosiglitazone-rich diet (3mg/kg/d) or regular rat chow
(control diet group) and subjected to ischemia-reperfusion (n=9 each group). A third
group of rats was fed regular chow and subjected to thoracotomy and left coronary isola-
tion (sham ischemia-reperfusion). At the end of the study, hearts were harvested for inf-
arct size determination as well as immunohistochemistry and Ang II AT1 and AT2
receptor mRNA determination by real-time reverse transcription polymerase chain reac-
tion (RT-PCR). The expression of mitogen-activated protein kinase (P42/44 MAPK) and
protein kinase B/Akt was assessed by Western blotting.
Results
The cardioprotective effects of rosiglitazone were confirmed by 58% reduction in infarct
size (P<0.05) and preservation of myocardial contractility (decline in ± dP/dt 75% less in
the rosiglitazone-rich diet group) during reperfusion (P<0.005). Importantly, Ang II AT2
receptor mRNA expression was markedly (≅100-fold) increased in the hearts from the
rats on rosiglitazone-rich diet as compared to those on the control-diet (P<0.005). The
Ang II AT1 receptor expression, which was increased in the control-diet group subjected,
was suppressed (≅8-fold) by rosiglitazone (P<0.005). P42/44 MAPK was increased in the
cotrol diet group, and this effect was ameliorated by rosiglitazone. Akt expression was
similar among the three groups, suggesting that insulin signaling was not involved in car-
dioprotection by rosiglitazone.
Conclusion
